Latest
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
The TOPAZ-1 trial evaluated durvalumab plus chemotherapy for patients with advanced biliary tract cancer
Cholangiocarcinoma Foundation Australia is registered as a charity with the Australian Charities and Not-for-Profits Commission (ACNC). Cholangiocarcinoma Foundation Australia has Deductible Gift Recipient (DGR) status with the Australian Tax Office. Donations over $2 or more are tax-deductible. ABN: 93 665 038 102
Shaping The Future
The Empowered Patient is uniquely positioned and equipped to understand, engage, and succeed by utilizing a process that integrates scientific advancements, evidence-based medicine, and human resilience attributes into a comprehensive response strategy.
Fully embracing the concept of an empowered patient will advance science, reshape the healthcare response, and close the unattended gap between early detection and late-stage diagnosis.